Log in

Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Needham & Company LLC

Last updated on Tuesday, June 30, 2020 | 2020 MarketBeat

Gilead Sciences (NASDAQ:GILD)'s stock had its "hold" rating reissued by investment analysts at Needham & Company LLC in a report released on Tuesday, AnalystRatings.com reports.

Several other research analysts have also issued reports on GILD. Mizuho reaffirmed a "buy" rating and set a $81.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 13th. UBS Group lowered Gilead Sciences from a "buy" rating to a "neutral" rating and increased their price objective for the company from $77.00 to $80.00 in a report on Monday, April 27th. BMO Capital Markets lowered Gilead Sciences from an "outperform" rating to a "market perform" rating and set a $79.00 price objective on the stock. in a report on Monday, April 20th. Credit Suisse Group reissued a "sell" rating and issued a $60.00 price objective on shares of Gilead Sciences in a report on Friday, April 17th. Finally, ValuEngine lowered Gilead Sciences from a "hold" rating to a "sell" rating in a report on Friday, May 1st. Five research analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of "Hold" and an average price target of $79.65.

Shares of NASDAQ:GILD opened at $74.56 on Tuesday. The business's 50-day moving average is $75.47 and its 200 day moving average is $71.99. Gilead Sciences has a 1 year low of $60.89 and a 1 year high of $85.97. The firm has a market capitalization of $93.53 billion, a P/E ratio of 19.17, a P/E/G ratio of 3.37 and a beta of 0.68. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same period in the prior year, the company posted $1.67 EPS. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. On average, analysts expect that Gilead Sciences will post 6.4 EPS for the current year.

In other Gilead Sciences news, Director John Francis Cogan sold 2,413 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $79.52, for a total transaction of $191,881.76. Following the transaction, the director now owns 57,273 shares in the company, valued at $4,554,348.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the transaction, the executive vice president now owns 27,204 shares in the company, valued at approximately $2,155,372.92. The disclosure for this sale can be found here. Insiders have sold 37,731 shares of company stock worth $3,008,736 in the last quarter. 0.13% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Research Global Investors lifted its position in shares of Gilead Sciences by 12.7% in the first quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company's stock valued at $7,175,643,000 after acquiring an additional 10,849,434 shares in the last quarter. Capital International Investors lifted its position in shares of Gilead Sciences by 336.8% in the first quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company's stock valued at $4,214,200,000 after acquiring an additional 43,464,551 shares in the last quarter. Capital World Investors lifted its position in shares of Gilead Sciences by 123.0% in the first quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company's stock valued at $3,463,732,000 after acquiring an additional 25,555,467 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 3.1% in the fourth quarter. Bank of New York Mellon Corp now owns 29,067,984 shares of the biopharmaceutical company's stock valued at $1,888,838,000 after acquiring an additional 870,944 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 3.4% in the first quarter. Geode Capital Management LLC now owns 19,882,508 shares of the biopharmaceutical company's stock valued at $1,484,311,000 after acquiring an additional 658,471 shares in the last quarter. Institutional investors and hedge funds own 80.15% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Market Capitalization in the Stock Market

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Tech Stocks to Buy Now For a Post Coronavirus Economy

The Covid-19 pandemic has created a new “tech wreck”. But unlike the broad selloff at the end of 2018, this downturn has been more selective. Some stocks that looked like they were a little overbought have seen their share prices lowered.

In some cases, there was a legitimate reason for this. However, in other cases, it was likely a result of profit-taking disguised as something else. That’s the nature of a crisis. It gives investors the cover to do what they wanted to do anyway. But once investors start to sell, it can trigger a herd mentality.

And that’s when savvy investors start to look for opportunities. Because as Warren Buffett famously said, “Be greedy when others are fearful.” Tech stocks will lead the way back when the pandemic is over. Because if there’s one thing this moment in time is teaching us, it’s that we’re not going to be less dependent on technology. Businesses aren’t going to be doing less digital advertising. Consumers aren’t going to do less e-commerce.

But the fundamentals still matter. That’s why one of the common traits of many of these companies is that they have rock-solid balance sheets.

View the "7 Tech Stocks to Buy Now For a Post Coronavirus Economy".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.